Hypothesis

NAD+ decline in aged hematopoietic stem cells (HSCs) is not merely a passive consequence of damage; it actively tunes a SIRT1‑dependent transcriptional program that limits self‑renewal and promotes a quiescent, differentiation‑biased state as a protective response to inflammatory stress.

Mechanistic Rationale

Recent work shows that inflammation‑driven CD38 upregulation depletes NAD+ 3, lowering SIRT1 activity and creating a pseudohypoxic state 1. While SIRT1 loss is often viewed as deleterious, SIRT1 also deacetylates and represses key pro‑differentiation transcription factors such as PU.1 and C/EBPα 4. When NAD+ falls, SIRT1 activity drops, lifting this repression and allowing differentiation programs to proceed. However, in the inflammatory milieu of aged bone marrow, transient SIRT1 inhibition can be advantageous: it reduces the energetic cost of maintaining a highly proliferative epigenome and forces HSCs into a low‑metabolism, stress‑resistant state 2. Thus, NAD+ decline functions as a rheostat that couples metabolite availability to SIRT1‑mediated restraint of lineage commitment, preserving the stem cell pool under stress.

Testable Predictions

1. In aged HSCs, pharmacologically raising NAD+ (e.g., with NR or CD38 inhibitor) will increase SIRT1 activity and thereby increase expression of PU.1 and C/EBPα, leading to accelerated myeloid differentiation and reduced long‑term repopulation capacity.
2. Genetic ablation of SIRT1 in young HSCs will mimic the aged transcriptional profile (high PU.1/C/EBPα, low self‑renewal genes) even when NAD+ levels are normal.
3. Combining NAD+ restoration with SIRT1 knockdown in aged mice will rescue the differentiation bias caused by NAD+ elevation alone, restoring balanced output.
4. Single‑cell ATAC‑seq will reveal that NAD+ elevation reduces chromatin accessibility at quiescence‑associated loci while increasing accessibility at myeloid enhancers, an effect abrogated by SIRT1 loss.

Experimental Approach

• Isolate LT‑HSCs from young (3 mo) and old (24 mo) CD38‑wildtype and CD38‑knockout mice.
• Treat ex vivo with NR (1 g kg⁻¹ day⁻¹) or vehicle for 48 h, measure NAD+ levels, SIRT1 activity (fluorometric deacetylase assay), and PU.1/C/EBPα protein by intracellular flow.
• Perform competitive repopulation assays (1 × 10⁴ donor cells) to assess long‑term chimerism at 16 weeks.
• In parallel, generate Vav‑Cre;Sirt1^fl/fl mice to delete SIRT1 specifically in hematopoietic cells and repeat NAD+ supplementation.
• For mechanistic depth, conduct scRNA‑seq and scATAC‑seq on sorted HSCs from each condition to map transcriptional and chromatin changes.

Falsification: If NAD+ elevation does not increase PU.1/C/EBPα expression or does not impair repopulation capacity, or if SIRT1 loss fails to reproduce the aged differentiation bias, the hypothesis that NAD+ decline functions as a rheostat via SIRT1‑mediated transcriptional restraint would be refuted.

References

[1] https://doi.org/10.1016/j.cell.2013.11.037 [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC12809054/ [3] https://doi.org/10.1016/j.bbrc.2019.03.199 [4] https://doi.org/10.1016/j.cmet.2018.03.016